

**Ref:** EPL/CS/SE/0004/2026**Date:** January 22, 2026

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Intimation for Earnings Call – Q3 FY26**

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that the **Earnings Call for Investors/ Analysts** will be held on **Wednesday, February 04, 2026 at 04:00 p.m. (IST)** to discuss the Company's Unaudited Financial Results (Standalone And Consolidated) and performance for the quarter and nine months ended December 31, 2025.

The details of the aforesaid earnings call for Investors/ Analysts is enclosed.

The transcript and the audio recording of the Earnings Call will be made available on the Company's website i.e. [www.emcure.com](http://www.emcure.com) and will be intimated accordingly.

You are requested to take the above information on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Tajuddin Shaikh**  
Chief Financial Officer

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251



## **Emcure Pharmaceuticals Ltd. Q3FY26 Results Earnings Call**

**Date: Wednesday, Feb 04, 2026**

**Time: 4:00 pm – 5:00 pm IST**

Dial – in Numbers:

Universal Access Number:

+91 22 6280 1220

+91 22 7115 8122

Hong Kong: 800 964 448

Singapore: 800 101 2045

UK: 080 8101 1573

USA: 186 674 62133

**[To pre-register online, please click here](#)**

*For any clarification, please contact:*

E-mail: [investor.relations@emcure.com](mailto:investor.relations@emcure.com)